{'fraction_non_alphanumeric': 0.019261637239165328, 'fraction_numerical': 0.008025682182985553, 'mean_word_length': 5.058252427184466, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Cognitive disorders in stroke patients: the possibilities of pharmacological correction].

OBJECTIVE
To determine the efficacy and safety of cellex in treatment of cognitive disorders in acute ischemic stroke (IS).


MATERIAL AND METHODS
The study involved 246 patients with acute IS. Patients were randomly divided into two groups depending on the use of cellex or placebo along with basic treatment during 10 days. The dynamics of neuropsychological status was evaluated.


RESULTS AND CONCLUSION
In IS patients, treatment with cellex have led to more rapid and marked reduction of mild and moderate cognitive disorders.